Mode
Text Size
Log in / Sign up
N/A N=26 Treatment

Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Depression

Depression · Major Depressive Disorder · tACS

Enrolled (actual)
26
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Change in Hamilton Depression Rating Scale 17-item (HDRS-17) — -12.04 units on a scale — p=<0.0005

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Closed-loop tACS (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Electromedical Products International, Inc.
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Hamilton Depression Rating Scale 17-item (HDRS-17)
-8.36 <0.0005 sig
SECONDARY
Change in Hamilton Depression Rating Scale 17-item (HDRS-17)
-8.36 <0.0005 sig
SECONDARY
Response/Remission of Depression
12; 13; 21; 4; 10; 15
SECONDARY
Change in Quick Inventory of Depressive Symptomatology (QIDS)
-3.88; -5.96; -7.48 <0.0005 sig
SECONDARY
Change in Altman Self-Rating Mania Scale (ASRM)
0.88; 1.92; 1.92 <0.0005 sig
SECONDARY
Change in Snaith-Hamilton Pleasure Scale (SHAPS)
-2.60; -3.48; -3.76 <0.0005 sig
SECONDARY
Change in Depression Anxiety and Stress Scale (DASS-42)
-12.52; -21.44; -24.08; -6.52; -11.00; -12.20 <0.0005 sig
SECONDARY
Change in State-Train Anxiety Inventory (STAI)
-3.08; -5.16; -6.16 0.021 sig
SECONDARY
Change in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF)
SECONDARY
Change in Clinical Global Impression Scale (CGI)
2.56; 1.68; 4.04; 2.36; 1.76 <0.0005 sig

Summary

The purpose of this research study is to study closed-loop transcranial alternating current stimulation (tACS) to determine its effects on symptoms of depression in people with major depressive disorder.

Eligibility Criteria

Inclusion Criteria

  • Ages 18-70 years
  • Diagnostic and Statistical Manual, 5th Edition (DSM-5) diagnosis of MDD; unipolar, non-psychotic
  • Hamilton Rating Depression Rating Scale (HRDS-17) score >8
  • Low suicide risk as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) triage form (no intent or plan)
  • Capacity to understand all relevant risks and potential benefits of the study (informed consent)

Exclusion Criteria

  • DSM-5 diagnosis of severe alcohol use disorder (AUD) within the last 12 months.
  • DSM-5 diagnosis of moderate to severe substance use disorder (excluding tobacco) within the last 12 months.
  • Lifetime history of bipolar disorder, psychotic disorder, schizophrenia, autism
  • Current use of benzodiazepines > 20mg diazepam/d equivalent
  • Antidepressant dose change within the last 2 weeks
  • Initiated new antidepressant within the last 4 weeks
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05772702). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search